The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Drug–target residence time: critical information for lead optimization
Open accessAbstract
Summary of recent advances Failure due to poor in vivo efficacy is a primary contributor to attrition during the development of new chemotherapeutics. Lead optimization programs that in their quest for efficacy focus solely on improving the affinity of drug-target binding are flawed, since this approach ignores the fluctuations in drug concentration that occur in vivo. Instead the lifetime of the drug-target complex must also be considered, since drugs only act when they are bound to their targets. Consequently, to improve the correlation between the in vitro and in vivo activity of drugs, measurements of drug-target residence time must be incorporated into the drug discovery process.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Histone deacetylases and cancer: causes and therapies
Marks, P. A., Rifkind, R. A., Richon, V. M., Breslow, R., Miller, T., & Kelly, W. K. (2001) · Nature reviews. Cancer · doi:10.1038/35106079 · Cited by 1,866 · cited 3×
“For the histone deacetylase inhibitor pimelic diphenylamide 106 [6,7], the percent target occupancy has been plotted as a function of time using a drug–target complex half-life (t1/2) of 8 h (the koff value for this inhibitor is 0.”
Drug-target residence time and its implications for lead optimization
Copeland, R. A., Pompliano, D. L., & Meek, T. D. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2082 · Cited by 1,464
Copeland, R. A. (2005) · PubMed · Cited by 1,092
The Behavior and Significance of Slow‐Binding Enzyme Inhibitors
Morrison, J. F., & Walsh, C. T. (1988) · Advances in Enzymology - and Related Areas of Molecular Biology · doi:10.1002/9780470123072.ch5 · Cited by 840
Residence Time of Receptor−Ligand Complexes and Its Effect on Biological Function
Tummino, P. J., & Copeland, R. A. (2008) · Biochemistry · doi:10.1021/bi8002023 · Cited by 544
Biochemical mechanisms of drug action: what does it take for success?
Swinney, D. C. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1500 · Cited by 394
Rawat, R., Whitty, A., & Tonge, P. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2235848100 · Cited by 330
Self-citationInhibitors of FabI, an Enzyme Drug Target in the Bacterial Fatty Acid Biosynthesis Pathway
Lu, H., & Tonge, P. J. (2008) · Accounts of Chemical Research · doi:10.1021/ar700156e · Cited by 254
Self-citationStructural basis and mechanism of enoyl reductase inhibition by triclosan
Stewart, M. J., Parikh, S., Xiao, G., Tonge, P. J., & Kisker, C. (1999) · Journal of Molecular Biology · doi:10.1006/jmbi.1999.2907 · Cited by 225
Self-citationPimelic Diphenylamide 106 Is a Slow, Tight-binding Inhibitor of Class I Histone Deacetylases
Chou, C. J., Herman, D., & Gottesfeld, J. M. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m807045200 · Cited by 223 · cited 3×
“For the histone deacetylase inhibitor pimelic diphenylamide 106 [6,7], the percent target occupancy has been plotted as a function of time using a drug–target complex half-life (t1/2) of 8 h (the koff value for this inhibitor is 0.”
Copeland, R. A. (2010) · Expert Opinion on Drug Discovery · doi:10.1517/17460441003677725 · Cited by 209
Luckner, S. R., Liu, N., am Ende, C. W., Tonge, P. J., & Kisker, C. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.090373 · Cited by 174
Self-citationZhou, P., & Barb, A. W. (2008) · Current Pharmaceutical Biotechnology · doi:10.2174/138920108783497668 · Cited by 162
Martin, M. D., Carter, K. J., Jean-Philippe, S. R., Chang, M., Mobashery, S., Thiolloy, S., Lynch, C. C., Matrisian, L. M., & Fingleton, B. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0537 · Cited by 134
Antimetastatic Activity of a Novel Mechanism-Based Gelatinase Inhibitor
Krüger, A., Arlt, M., Gerg, M., Kopitz, C., Bernardo, M. M., Chang, M., Mobashery, S., & Fridman, R. A. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3570 · Cited by 127
Lewandowicz, A., Tyler, P. C., Evans, G. B., Furneaux, R. H., & Schramm, V. L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.c300259200 · Cited by 126
Tachykinin Receptors as Therapeutic Targets in Stress-Related Disorders
Ebner, K., Sartori, S. B., & Singewald, N. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209788168074 · Cited by 121
Lu, H., England, K., Ende, C. W. A., Truglio, J. J., Luckner, S. R., Reddy, B. G., Marlenee, N. L., Knudson, S. E., Knudson, D. L., Bowen, R. A., et al. (2009) · ACS Chemical Biology · doi:10.1021/cb800306y · Cited by 113
Self-citationThe importance of drug-target residence time.
Zhang, R., & Monsma, F. J. (2009) · PubMed · Cited by 102
Swinney, D. C. (2006) · Current Topics in Medicinal Chemistry · doi:10.2174/156802606776743093 · Cited by 97
Swinney, D. C. (2008) · Pharmaceutical Medicine · doi:10.1007/bf03256679 · Cited by 79
Kim, Y. B., Kopcho, L. M., Kirby, M., Hamann, L. G., Weigelt, C. A., Metzler, W. J., & Marcinkeviciene, J. A. (2005) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2005.11.010 · Cited by 75
Lindström, E., von Mentzer, B., Påhlman, I., Ahlstedt, I., Uvebrant, A., Kristensson, E., Martinsson, R., Novén, A., de Verdier, J., & Vauquelin, G. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.124958 · Cited by 71
Rajagopalan, R., Misialek, S., Stevens, S., Myszka, D. G., Brandhuber, B. J., Ballard, J. A., Andrews, S. W., Seiwert, S. D., & Kossen, K. (2009) · Biochemistry · doi:10.1021/bi900038p · Cited by 61
Slow Onset Inhibition of Bacterial β-Ketoacyl-acyl Carrier Protein Synthases by Thiolactomycin
Machutta, C. A., Bommineni, G. R., Luckner, S. R., Kapilashrami, K., Ruzsicska, B. P., Simmerling, C. L., Kisker, C., & Tonge, P. J. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.077909 · Cited by 45
Self-citationEfavirenz Binding to HIV-1 Reverse Transcriptase Monomers and Dimers
Braz, V. A., Holladay, L. A., & Barkley, M. D. (2009) · Biochemistry · doi:10.1021/bi901579y · Cited by 40
Garvey, E. P., Schwartz, B. J., Gartland, M. J., Lang, S., Halsey, W. S., Sathe, G. M., Carter, H. L., & Weaver, K. L. (2009) · Biochemistry · doi:10.1021/bi802141y · Cited by 40
Update of KDBI: Kinetic Data of Bio-molecular Interaction database
Kumar, P., Han, B. C., Shi, Z., Jia, J., Wang, Y., Zhang, Y., Liang, L., Liu, Q. F., Ji, Z., & Chen, Y. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn839 · Cited by 26
Gooyit, M., Lee, M., Hesek, D., Boggess, B., Oliver, A. G., Fridman, R. A., Mobashery, S., & Chang, M. (2009) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2009.00898.x · Cited by 17
Tanaka‐Amino, K., Matsumoto, K., Hatakeyama, Y., Takakura, S., & Mutoh, S. (2009) · Acta Diabetologica · doi:10.1007/s00592-009-0096-5 · Cited by 5
(2009) · PubMed
Cited by
The resurgence of covalent drugs
Singh, J., Petter, R. C., Baillie, T. A., & Whitty, A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3410 · Cited by 1,873
How were new medicines discovered?
Swinney, D. C., & Anthony, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3480 · Cited by 1,812
Sulfur(VI) Fluoride Exchange (SuFEx): Another Good Reaction for Click Chemistry
Dong, J., Krasnova, L., Finn, M. G., & Sharpless, K. B. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201309399 · Cited by 1,390
Role of Molecular Dynamics and Related Methods in Drug Discovery
De Vivo, M., Masetti, M., Bottegoni, G., & Cavalli, A. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01684 · Cited by 1,297
Pathway and mechanism of drug binding to G-protein-coupled receptors
Dror, R. O., Pan, A. C., Arlow, D. H., Borhani, D. W., Maragakis, P., Shan, Y., Xu, H., & Shaw, D. E. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1104614108 · Cited by 730
Metadata
- Authors
- Lu, H., & Tonge, P. J.
- Venue
- Current Opinion in Chemical Biology
- Publisher
- Elsevier BV
- Published
- 2010-08
- Volume
- 14
- Issue
- 4
- Pages
- 467-474
- ISSN
- 1367-5931 (ISSN-L)
- OpenAlex
- W2040680919
- Cited by
- 432
- References
- 32
- FWCI
- 1.78
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.